LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade

The inability of CD8+ effector T cells (Teffs) to reach tumor cells is an important aspect of tumor resistance to cancer immunotherapy. The recruitment of these cells to the tumor microenvironment (TME) is regulated by integrins, a family of adhesion molecules that are expressed on T cells. Here, we show that 7HP349, a small-molecule activator of lymphocyte function???associated antigen-1 (LFA-1) and very late activation antigen-4 (VLA-4) integrin cell-adhesion receptors, facilitated the preferential localization of tumor-specific T cells to the tumor and improved antitumor response. 7HP349 monotherapy had modest effects on anti???programmed death 1???resistant (anti???PD-1???resistant) tumors, whereas combinatorial treatment synergized in cooperation with neutrophils in inducing cancer regression. 7HP349 intratumoral CD8+ Teff enrichment activity depended on CXCL12. We analyzed gene expression profiles using RNA from baseline and on treatment tumor samples of 14 melanoma patients. We identified baseline CXCL12 gene expression as possibly improving the likelihood or response to anti???CTLA-4 therapies. Our results provide a proof-of-principle demonstration that LFA-1 activation could convert a T cell??? exclusionary TME to a T cell???enriched TME through mechanisms involving cooperation with innate immune cells.

Automated summary

The small-molecule activator 7HP349 enhances the localization of tumor-specific T cells to tumors and improves antitumor response, with combinatorial treatment synergizing with neutrophils in inducing cancer regression.